In re Viropharma Inc. Securities Litigation’s Empirical Analysis
2014
Citation profile
1 district ·
Relationships
Applies 15 U.S.C. § 78J (§ 10 of the Securities Exchange Act of 1934) · 15 U.S.C. § 78T (§ 20 of the Securities Exchange Act of 1934) · 15 U.S.C. § 78U (§ 21d of the Securities Exchange Act of 1934) · 15 U.S.C. § 78U (§ 21e of the Securities Exchange Act of 1934) · 21 U.S.C. § 355 (Federal Food, Drug, and Cosmetic Act)
Relies on Bell Atlantic Corp. v. Twombly · Ashcroft v. Iqbal · Basic Inc. v. Levinson · Tellabs, Inc. v. Makor Issues & Rights, Ltd. · TSC Industries, Inc. v. Northway, Inc.
Most-quoted passages
The sentences later courts lift from this opinion, ranked by how many decisions quote each — the parts of the opinion doing the work. These counts are smaller than the citation total above because most of the 3 citing decisions cite the case generally; a passage count includes only decisions quoting that exact language verbatim.
“that statements regarding the likelihood and timing of FDA approval for a drug and the reasons for management's beliefs that such approval will occur fall under the statutory definition of 'forward-looking.'”
1 later decision quote this exact passage · from the majoritye.g. In re Egalet Corp.“public statements of confidence in the prospect of achieving an additional three years of exclusivity for [its drug], made while its [petition for exclusivity] was pending before the FDA.”
1 later decision quote this exact passage · from the majoritye.g. In re Egalet Corp.“Viropharma had privately received [information] from the FDA regarding the [FDA's] view”
1 later decision quote this exact passage · from the majoritye.g. In re Egalet Corp.
How this case has been treated — in progress
Whether each later court followed, distinguished, criticized, or overruled this decision. The treatment classification (task #35) runs highest-cited cases first and lights up here as it reaches this one.